CA Stock MarketDetailed Quotes
CSCI Cosciens Biopharma Inc
- 5.200
- +0.100+1.96%
15min DelayMarket Closed Oct 15 16:00 ET
16.20MMarket Cap-1414P/E (TTM)
5.200High5.200Low278Volume5.200Open5.100Pre Close1.44KTurnover9.00052wk High0.01%Turnover Ratio3.12MShares4.64052wk Low-3.675EPS TTM14.80MFloat Cap9.000Historical HighLossP/E (Static)2.85MShs Float4.640Historical Low-2.541EPS LYR0.00%Amplitude--Dividend TTM0.46P/B1Lot Size--Div YieldTTM
Cosciens Biopharma Inc Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 67.89%2.34M | -20.55%2.05M | -47.69%7.26M | -45.19%1.39M | -31.48%1.93M | -67.39%1.39M | -47.73%2.58M | 2.93%13.88M | -9.41%2.53M | -20.70%2.81M |
| Operating revenue | 67.89%2.34M | -20.55%2.05M | -47.69%7.26M | -45.19%1.39M | -31.48%1.93M | -67.39%1.39M | -47.73%2.58M | 2.93%13.88M | -9.41%2.53M | -20.70%2.81M |
| Cost of revenue | 155.13%1.52M | -17.57%1.15M | -25.74%4.28M | -26.52%1.17M | -1.54%1.13M | -54.20%595K | -29.04%1.4M | 9.22%5.76M | 115.47%1.59M | -6.80%1.15M |
| Gross profit | 2.76%819K | -24.05%901.72K | -63.26%2.98M | -76.76%218.92K | -52.19%794.54K | -73.16%797K | -60.10%1.19M | -1.12%8.12M | -54.24%942.03K | -28.12%1.66M |
| Operating expense | 139.35%4.57M | 74.52%2.71M | 89.30%7.7M | 100.38%2.37M | 117.32%1.89M | 51.77%1.91M | 71.86%1.56M | -27.64%4.07M | -8.53%1.18M | -48.98%869.8K |
| Selling and administrative expenses | 149.51%3.04M | 46.21%1.65M | 104.61%5.62M | 143.22%1.83M | 128.14%1.46M | 45.76%1.22M | 82.33%1.13M | 6.61%2.75M | 16.94%753.48K | 5.81%640.01K |
| -Selling and marketing expense | ---- | -44.20%3.37K | 40.12%30.52K | -11.24%5.89K | 93.33%8.71K | ---- | 42.47%6.05K | -41.07%21.78K | -32.71%6.64K | 15.90%4.5K |
| -General and administrative expense | 149.51%3.04M | 46.69%1.65M | 105.13%5.59M | 144.59%1.83M | 128.38%1.45M | 47.02%1.22M | 82.60%1.12M | 7.31%2.73M | 17.71%746.84K | 5.74%635.51K |
| Research and development costs | 121.42%1.53M | 150.02%1.06M | 57.38%2.07M | 25.43%540.11K | 87.18%430.12K | 63.69%691K | 49.04%424.14K | -56.67%1.32M | -33.77%430.61K | -79.11%229.79K |
| Operating profit | -237.07%-3.76M | -392.70%-1.81M | -216.38%-4.72M | -789.79%-2.15M | -238.32%-1.1M | -165.13%-1.11M | -117.76%-367.79K | 56.42%4.05M | -131.67%-242.06K | 30.44%792.14K |
| Net non-operating interest income (expenses) | 8.33%-22K | 4.84%-62.48K | 382.15%190.78K | 601.50%303.26K | -0.83%-23.14K | 3.89%-24K | 6.90%-65.65K | 58.33%-67.62K | 248.89%43.23K | 22.33%-22.95K |
| Non-operating interest income | ---- | ---- | 378.86%328.82K | ---- | ---- | ---- | ---- | --68.67K | ---- | ---- |
| Non-operating interest expense | -8.33%22K | -12.87%21.77K | 0.86%96.59K | -2.24%24.57K | 0.83%23.14K | -3.89%24K | -5.56%24.99K | -19.62%95.76K | -13.40%25.13K | -22.33%22.95K |
| Total other finance cost | ---- | 0.10%40.7K | 2.31%41.46K | 224.26%997.3673 | ---- | ---- | -7.70%40.66K | -6.06%40.52K | 1,683.36%307.5838 | ---- |
| Other net income (expenses) | 4,274.42%1.88M | -9.51%64.14K | -72.98%73.6K | -868.89%-183.12K | -27.39%143.97K | -71.12%43K | 171.92%70.88K | 71.70%272.4K | -89.69%23.82K | 82.76%198.28K |
| Gain on sale of security | --1.77M | 231.11%24.6K | -111.51%-23.87K | 43.51%-27.29K | -66.57%61.36K | ---- | 78.06%-18.77K | 448.62%207.37K | 0.85%-48.31K | 51.15%183.55K |
| Other non-operating income (expenses) | 153.49%109K | -55.90%39.53K | 49.87%97.47K | -316.05%-155.83K | 461.00%82.6K | 507.52%43K | 789.18%89.65K | -69.64%65.04K | -74.22%72.13K | 187.27%14.72K |
| Income before tax | -73.15%-1.9M | -399.35%-1.81M | -204.57%-4.45M | -1,062.01%-2.03M | -200.76%-974.85K | -159.70%-1.1M | -119.07%-362.56K | 64.56%4.26M | -118.11%-175.01K | 40.99%967.47K |
| Income tax | -101.70%-474K | -428.39%-411.54K | -188.65%-900.61K | -1,123.63%-381.33K | -191.61%-209.42K | -154.22%-235K | -117.34%-77.89K | 2,019.77%1.02M | 41.11%-31.16K | 228.6K |
| Earnings from equity interest net of tax | ||||||||||
| Net income | -65.35%-1.42M | -391.40%-1.4M | -209.56%-3.55M | -1,048.66%-1.65M | -203.60%-765.44K | -161.39%-860K | -119.60%-284.67K | 22.77%3.24M | -114.11%-143.85K | 7.68%738.87K |
| Net income continuous operations | -65.35%-1.42M | -391.40%-1.4M | -209.56%-3.55M | -1,048.66%-1.65M | -203.60%-765.44K | -161.39%-860K | -119.60%-284.67K | 22.77%3.24M | -114.11%-143.85K | 7.68%738.87K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -65.35%-1.42M | -391.40%-1.4M | -209.56%-3.55M | -1,048.66%-1.65M | -203.60%-765.44K | -161.39%-860K | -119.60%-284.67K | 22.77%3.24M | -114.11%-143.85K | 7.68%738.87K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -65.35%-1.42M | -391.40%-1.4M | -209.56%-3.55M | -1,048.66%-1.65M | -203.60%-765.44K | -161.39%-860K | -119.60%-284.67K | 22.77%3.24M | -114.11%-143.85K | 7.68%738.87K |
| Diluted earnings per share | -36.17%-0.64 | -306.87%-0.6272 | -202.31%-1.9165 | -7,001.68%-0.9813 | -200.61%-0.3117 | -171.46%-0.47 | -122.71%-0.1541 | 40.92%1.8732 | -95.73%0.0142 | -6.73%0.3098 |
| Basic earnings per share | -36.17%-0.64 | -306.87%-0.6272 | -202.31%-1.9165 | -7,001.68%-0.9813 | -200.61%-0.3117 | -171.46%-0.47 | -122.71%-0.1541 | 40.92%1.8732 | -95.73%0.0142 | -6.73%0.3098 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Latest Price
% Chg
No Data